Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction
Our study highlights the potential of the selective ADAM10 inhibitor VTH144 as a promising therapeutic candidate for improving cardiac function and reducing the risk of heart failure following myocardial infarction.
Authors
- Kristina Lorenz (ORCID: https://orcid.org/0000-0002-5747-2207)
- Ben Wielockx (ORCID: https://orcid.org/0000-0002-4923-2596)
- Fred Rasmussen
- Susanne Nedergaard Grell
- Johannes Richard Soltwedel (ORCID: https://orcid.org/0000-0003-1273-2412)
- Jay S. Marks
- Paul Säftig (ORCID: https://orcid.org/0000-0003-2637-7052)
- F. Mejía
- Patrick Diaba‐Nuhoho (ORCID: https://orcid.org/0000-0002-8672-6640)
- Michael Wagner (ORCID: https://orcid.org/0000-0002-6300-5752)
- Ali El‐Armouche
- Charles L. Prince
- Peter Mirtschink (ORCID: https://orcid.org/0000-0001-5832-1673)
- Erik Klapproth (ORCID: https://orcid.org/0000-0002-0731-194X)
- Susanne Kämmerer (ORCID: https://orcid.org/0009-0008-1895-4538)
- Marcia L. Moss (ORCID: https://orcid.org/0000-0003-2117-0431)
- Paul Leubauer
Institutions
- University of Würzburg (DE)
- Christian-Albrechts-Universität zu Kiel (DE)
- Verve Therapeutics (United States) (US)
- Leibniz Institute for Analytical Sciences - ISAS (DE)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1111/bph.70201
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00